Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 310

1.

Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.

Kraeber-Bodéré F, Bodet-Milin C, Niaudet C, Saï-Maurel C, Moreau A, Faivre-Chauvet A, Thomare P, Deleris G, Estieu-Gionnet K, Bikfalvi A, Barbet J, Paris F.

J Nucl Med. 2010 Apr;51(4):624-31. doi: 10.2967/jnumed.109.070714.

PMID:
20351352
[PubMed - indexed for MEDLINE]
Free Article
2.

Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.

Kraeber-Bodéré F, Saï-Maurel C, Campion L, Faivre-Chauvet A, Mirallié E, Chérel M, Supiot S, Barbet J, Chatal JF, Thédrez P.

Mol Cancer Ther. 2002 Feb;1(4):267-74.

PMID:
12467222
[PubMed - indexed for MEDLINE]
Free Article
3.

Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.

Kraeber-Bodéré F, Faibre-Chauvet A, Saï-Maurel C, Gautherot E, Fiche M, Campion L, Le Boterff J, Barbet J, Chatal JF, Thédrez P.

J Nucl Med. 1999 Jan;40(1):198-204.

PMID:
9935077
[PubMed - indexed for MEDLINE]
Free Article
4.

Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.

Kraeber-Bodéré F, Faivre-Chauvet A, Saï-Maurel C, Campion L, Fiche M, Gautherot E, Le Boterff J, Barbet J, Chatal JF, Thédrez P.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3183s-3189s.

PMID:
10541362
[PubMed - indexed for MEDLINE]
5.

Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.

Salaun PY, Bodet-Milin C, Frampas E, Oudoux A, Saï-Maurel C, Faivre-Chauvet A, Barbet J, Paris F, Kraeber-Bodéré F.

Cancer. 2010 Feb 15;116(4 Suppl):1053-8. doi: 10.1002/cncr.24792.

PMID:
20127950
[PubMed - indexed for MEDLINE]
Free Article
6.

Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine.

Stein R, Chen S, Reed L, Richel H, Goldenberg DM.

Cancer. 2002 Jan 1;94(1):51-61.

PMID:
11815960
[PubMed - indexed for MEDLINE]
Free Article
7.

Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.

Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Fränk M, Schmidberger H, Raue F, Becker W.

Cancer Res. 1997 Dec 1;57(23):5309-19.

PMID:
9393755
[PubMed - indexed for MEDLINE]
Free Article
8.

Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.

Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL.

Cancer Res. 2002 Aug 1;62(15):4263-72.

PMID:
12154028
[PubMed - indexed for MEDLINE]
Free Article
9.

Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.

Hosono M, Hosono MN, Kraeber-Bodéré F, Devys A, Thédrez P, Fiche M, Gautherot E, Barbet J, Chatal JF.

J Nucl Med. 1998 Sep;39(9):1608-13.

PMID:
9744353
[PubMed - indexed for MEDLINE]
Free Article
10.

Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.

Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M, Ringel MD, Francis GL.

Thyroid. 2002 Nov;12(11):953-61.

PMID:
12490072
[PubMed - indexed for MEDLINE]
11.

Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.

Stein R, Juweid M, Mattes MJ, Goldenberg DM.

Cancer Biother Radiopharm. 1999 Feb;14(1):37-47.

PMID:
10850286
[PubMed - indexed for MEDLINE]
13.

Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts.

Kinuya S, Kawashima A, Yokoyama K, Koshida K, Konishi S, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N.

J Nucl Med. 2002 Aug;43(8):1084-9.

PMID:
12163635
[PubMed - indexed for MEDLINE]
Free Article
14.

[Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].

Lu J, Jin J, Xu WL.

Zhonghua Er Ke Za Zhi. 2006 Mar;44(3):228-33. Chinese.

PMID:
16624066
[PubMed - indexed for MEDLINE]
15.

Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.

Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7070s-7074s.

PMID:
16203804
[PubMed - indexed for MEDLINE]
Free Article
16.

Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.

Kelly MP, Lee FT, Smyth FE, Brechbiel MW, Scott AM.

J Nucl Med. 2006 Apr;47(4):716-25.

PMID:
16595507
[PubMed - indexed for MEDLINE]
Free Article
17.

Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy.

Kinuya S, Yokoyama K, Koshida K, Mori H, Shiba K, Watanabe N, Shuke N, Bai J, Michigishi T, Tonami N.

Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):981-5. Epub 2004 Feb 28.

PMID:
14991242
[PubMed - indexed for MEDLINE]
18.

Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.

Stein R, Govindan SV, Chen S, Reed L, Richel H, Griffiths GL, Hansen HJ, Goldenberg DM.

J Nucl Med. 2001 Jun;42(6):967-74.

PMID:
11390564
[PubMed - indexed for MEDLINE]
Free Article
19.

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.

Clin Cancer Res. 2000 Oct;6(10):3855-63.

PMID:
11051230
[PubMed - indexed for MEDLINE]
Free Article
20.

Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.

Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH.

Cancer Res. 2001 Jun 15;61(12):4716-22.

PMID:
11406542
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk